## **AGENDA**



POETIC Summer Meeting Alberta Children's Hospital The Banff Centre 107 Tunnel Drive Banff, Alberta, Canada

Pediatric Oncology Experimental Therapeutics Investigators' Consortium	1
Time	Session
Tuesday, July 26th	
4:00 - 5:00 PM	PI Meeting (Closed Meeting)
6:00 - 7:00 PM	
MST	Board of Directors Meeting (Closed Meeting)
7-00 DM	Dinner
7:00 PM	Closed to Board of Directors
Wednesday, July 27th	
8:00 - 8:45 AM	Registration/Breakfast
	Greetings/Introductions
	Dr. Aru Narendran, Principal Investigator, POETIC, Alberta Children's Hospital, Director, POETIC Preclinical Development Laboratory
	Trospital, Birector, For Treelinear Bevelopment Eaboratory
	Welcome Address
	Dr. Victor Lewis
	Chief, Section of Pediatric Oncology and Blood and Marrow Transplant,
	Alberta Children's Hospital
9:00 - 9:15 AM	Dr. Tanya Trippett, Co-Founder and Director, POETIC
	Epigenetics initiatives in Alberta
9:15- 9:45 AM	Raja Singh, MD, PhD, Director, Alberta Epigenomics Network
0.45.40.45.44	Epigenetics of transgenerational response to stress
9:45 -10:15 AM	Igor Kovalchuk, MD, PhD, University of Lethbridge
10:15 -10:30 AM	Thrombosis management in Cancer patients Borys Sydoruk, Leo Pharma
10:30 -10:45 AM	Break
10:45 -11:15 AM	Invited Lecture: Proteomics in Cancer  Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center
10:45 -11:15 AM	Overview of the Strategic Plan for POETIC Translational Genome
	Program
	Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
	Aru Narendran, MD, PhD, Alberta Children's Hospital
11:15 -11:45 PM	Ethics of Genomics Research
11:45 -12:00 PM	Aru Narendran, MD, PhD, Alberta Children's Hospital
12:00 -1:00 PM	Lunch
Afternoon Session	
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	POETIC Translational Genomics Session
1:00 - 4:00 PM	Comprehensive Testing of Molecular Consmiss and Improved asia
	Comprehensive Testing of Molecular, Genomic and Immunologic
	Profiling in Pediatric Tumors - a POETIC Biology Study
	Srikanth Ambati, MD, Memorial Sloan Kettering Cancer Center
1:00 -1:30 PM	

	Update from POETIC Preclinical Developmental Laboratory Aru Narendran, MD, PhD, Alberta Children's Hospital
1:30 - 2:00 PM	Aru Narendran, MD, PhD, Alberta Children's Hospital
	Update from POETIC Exosome Developmental Laboratory
2:00 - 2:30 PM	David Lyden, MD, PhD, Weill Cornell Medical Center
2:30 - 2:45 PM	Break
	Update from Robert Arceci Epigenomics Program
	DNA Program
2:45 - 3:15 PM	Bodour Salhia, PhD, University of Southern California
	Update from Robert Arceci Epigenomics Program
	RNA Program
3:15 - 3:45 PM	Olga Kovalchuk, MD, PhD, University of Lethbridge
	POETIC Precision Biobank
	Presentation by Dr. Michael Roerhl and Genomics Team followed by open
3:45 - 4:05 PM	discussion working session
4:05 - 4:15 PM	Break
	Preclinical and Clinical Development of PV-10
	Eric Wachter, PhD, Chief Technology Officer and Director, Provectus
	Biopharmaceuticals, Inc.
	Peter Culpepper, COO and Interim CEO, Provectus Biopharmaceuticals,
4:15 - 5:15 PM	Inc.
	Pipeline Presentation
	Su Kim, MD, PhD, Medical Director, AbbVie Global Pharmaceutical
5:15- 6:00 PM	Research and Development
7:00 PM	Dinner

7:30 - 8:30 AM  Registration/Breakfast  POETIC Partner of Distinction Award  Christine McIver, M.S.M., LLD (Hon), CFRE  Founder & Chief Executive Officer  Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (C Session)	7:30 - 8:30 AM  Registration/Breakfast  POETIC Partner of Distinction Award Christine McIver, M.S.M., LLD (Hon), CFRE Founder & Chief Executive Officer  8:30 - 8:45 AM  Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (Closesion) Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial SI Kettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM  Break  Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	7:15 - 8:15 AM	Transport from hotel
POETIC Partner of Distinction Award Christine McIver, M.S.M., LLD (Hon), CFRE Founder & Chief Executive Officer Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (C Session) Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial S Kettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	POETIC Partner of Distinction Award Christine McIver, M.S.M., LLD (Hon), CFRE Founder & Chief Executive Officer Kids Cancer Care Foundation of Alberta Phase I/II Trial of Neratinib in Pediatric Malignancies (Closesion) Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial SI Kettering Cancer Center Anna Butturini, MD, PUMA Oncology Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center 10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	7.13 - 6.13 AM	Transport from note:
Christine McIver, M.S.M., LLD (Hon), CFRE Founder & Chief Executive Officer  Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (C Session)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial S Kettering Cancer Center  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Christine McIver, M.S.M., LLD (Hon), CFRE Founder & Chief Executive Officer Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (Closession) Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Slokettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center 10:00 - 10:30 AM Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	7:30 - 8:30 AM	Registration/Breakfast
8:30 – 8:45 AM  Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (C Session)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial S Kettering Cancer Center  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center	8:30 – 8:45 AM  Phase I/II Trial of Neratinib in Pediatric Malignancies (Closesion)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Slikettering Cancer Center  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  10:00 - 10:30 AM  Break  Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid  10:45 - 11:15 AM  Phase I Study of Carfilzomib, MD and Aru Narendran, MD, PhD		POETIC Partner of Distinction Award
8:30 – 8:45 AM  Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (C Session)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial S Kettering Cancer Center  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center	8:30 – 8:45 AM  Kids Cancer Care Foundation of Alberta  Phase I/II Trial of Neratinib in Pediatric Malignancies (Closession)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Slee Kettering Cancer Center  8:45- 10:00 AM  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM  Break  Phase I Study of Carfilzomib, Cyclophosphamide, Etoposida  10:45 - 11:15 AM  Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		Christine McIver, M.S.M., LLD (Hon), CFRE
Phase I/II Trial of Neratinib in Pediatric Malignancies (C Session)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial State Kettering Cancer Center  8:45-10:00 AM Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Phase I/II Trial of Neratinib in Pediatric Malignancies (Closession)  Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Slikettering Cancer Center  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM  Break  Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid  Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		Founder & Chief Executive Officer
Session) Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial S Kettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Session) Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Slikettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	8:30 - 8:45 AM	
Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial S Kettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Co-PI: Śrikanth Ambati, MD and Tanya Trippett, MD Memorial Slikettering Cancer Center  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed
8:45- 10:00 AM  Mettering Cancer Center Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	8:45- 10:00 AM  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		•
8:45- 10:00 AM  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center	8:45- 10:00 AM  Anna Butturini, MD, PUMA Oncology  Update from P2C2/Protocol Review Committee/ DCC  Cynthia Herzog, MD, MD Anderson Cancer Center  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM  Break  Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid  10:45 - 11:15 AM  Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD Memorial Sloan
Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Update from P2C2/Protocol Review Committee/ DCC Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		
Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Cynthia Herzog, MD, MD Anderson Cancer Center Lisa McGregor, MD, Pennsylvania State Medical Center Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	8:45- 10:00 AM	
Lisa McGregor, MD, Pennsylvania State Medical Center  10:00 - 10:30 AM  Lisa McGregor, MD, Pennsylvania State Medical Center  Joseph DeStefano, Memorial Sloan Kettering Cancer Center	Lisa McGregor, MD, Pennsylvania State Medical Center  10:00 - 10:30 AM Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid  10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		
10:00 - 10:30 AM Joseph DeStefano, Memorial Sloan Kettering Cancer Center	10:00 - 10:30 AM  Joseph DeStefano, Memorial Sloan Kettering Cancer Center  10:30 - 10:45 AM  Break  Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM  Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		
<b>3</b>	10:30 - 10:45 AM Break Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid 10:45 - 11:15 AM Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		
10:30 - 10:45 AM Break	10:45 - 11:15 AM Phase I Study of Carfilzomib, Cyclophosphamide, Etoposid Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	10:00 - 10:30 AM	Joseph DeStefano, Memorial Sloan Kettering Cancer Center
	10:45 - 11:15 AM   Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD	10:30 - 10:45 AM	Break
Phase I Study of Carfilzomib, Cyclophosphamide, Etoposi	10:45 - 11:15 AM   Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD		Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide
	, , ,	10:45 - 11:15 AM	
. , ,	Preclinical and Clinical Development of Taurolidine NanoP		Preclinical and Clinical Development of Taurolidine NanoPro™
<b>11:15-12:15 PM</b> Stephen Haworth, MD, Medical Officer, Cormedix, Inc.		11:15-12:15 PM	<u>=</u>
		2:15-1:00 PM	Lunch

3:15-4:00 PM	Outtake
2:45-3:15 PM	LOI: Phase I/II trial using Selinexor with Fludarabine and Cytarabine Norman Lacayo, MD, Lucile Packard Children's Hospital Jeffrey Rubinitz, MD, PhD, St. Jude Children's Research Hospital Karyopharm
2:30- 2:45 PM	Break
2:00-2:30 PM	Single Cell Phosphoprotein Profiling in Leukemia Kara Davis, MD, Lucile Packard Children's Hospital
1:00-2:00 PM	Sanofi Pipeline Presentation  Joanne Lager, MD, Head of Development, Oncology, Sanofi